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Abstract Heart failure is a major health problemworldwide
and, despite effective therapies, is expected to grow by
almost 50 % over the next 15 years. Five-year mortality
remains high at 50 % over 5 years. Because of the economic
burden and large impact on quality of life, substantial effort
has focused on treatments with multiple medical (beta-
blockers, angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers (ARB), aldosterone antago-
nists, and combination of ARB/neprilysin blockers, ivabra-
dine) and device therapies (ICD, CRT) which have been
implemented to reduce disease burden and mortality. How-
ever, in the past decade only two new medical therapies and
no devices have been approved by the US FDA for the
treatment of heart failure. This review highlights the pre-
clinical and clinical literature, and the implantation proce-
dure, related to a relatively new therapeutic device for heart
failure; cardiac contractility modulation (CCM). CCM
delivers a biphasic high-voltage bipolar signal to the RV
septum during the absolute refractory period, eliciting an
acute increase in global contractility, and chronically pro-
ducing a sustained improvement in quality of life, exercise
tolerance, and heart failure symptoms. The technology is
used commercially in Europe with nearly 3000 patients
implanted worldwide. Indications include patients with
reduced EF and normal or slightly prolonged QRS duration,
thus filling an important therapeutic gap among the 2/3 of
patients with heart failure who do not meet criteria for CRT.
The mechanism by which CCM provides benefit can be seen
at the cellular level where improved calcium handling
(phosphorylation of phospholamban, upregulation of
SERCA-2A), reversal of the fetal myocyte gene program
associated with heart failure, and reverse remodeling are
observed. Recent retrospective studies indicate a long-term
mortality benefit. A pivotal randomized controlled study is
currently being completed in theUSA.CCMappears to be an
effective, safe technology for the treatment of heart failure
with reduced ejection fraction.
Keywords Cardiac contractility modulation  Device 
Calcium handling  SERCA2A  Electrical therapy  HFrEF
Epidemiology and magnitude of the problem
It is estimated that the prevalence of heart failure among
American adults was 5.7 million in 2012 [1], a number
expected to climb 46 % by 2030 [2]. This growth in numbers
is likely multifactorial. It reflects more effective treatment of
acute coronary syndromes resulting in fewer deaths from
acute myocardial infarction but more cardiac dysfunction in
the remaining survivors. It may also reflect improved treat-
ment with longer survival of patients with dilated car-
diomyopathies of various etiologies. Worldwide the
prevalence of heart failure is estimated to exceed 25 million
[3] but has been difficult to calculate in recent decades due to
lack of uniformity in data collection, especially in develop-
ing countries. In 2009, heart failure was the most common
reason for hospital admission in Germany [4].
Above the age of 65, heart failure incidence approaches
1 in 100 people. At age 40, the lifetime risk of developing
heart failure averages 20 %, but is higher in those with
hypertension [1]. Gender and racial disparities are preva-
lent. Annual rates of heart failure in women are less than in
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men for all age groups (Fig. 1; adapted from Mozaffarian
et al. [1]). The risk of developing heart failure is greater
among African Americans than Hispanics, Caucasians, or
Chinese Americans (Fig. 2) [1].
In the USA, 1 in 9 death certificates indicates presence
of heart failure, with heart failure being the underlying
cause of death in more than 58,000 Americans each year
[1]. Interestingly, the number of deaths attributed to heart
failure was similar in 2011 (284,000) compared to rates in
1995 (287,000) [1]. However, survival has improved over
time [5], even though the 5-year mortality rate from heart
failure remains high at around 50 % [5, 6]. Much of the
improvement in survival relates to the extensive clinical
trials yielding several classes of drugs and devices that are
effective in reducing symptoms and in many cases
improving survival in patients with heart failure.
Ambulatory medical therapy for heart failure
Over the past few decades, there has been substantial
progress in treating heart failure with reduced ejection
fraction (HFrEF). The intense scientific and commercial
interest in heart failure is the result of its high prevalence.
Since the advent of percutaneous interventions for acute
coronary syndromes, more patients are surviving their
myocardial infarctions but at the expense of developing
heart failure. In 2012, heart failure was the #1 reason for
hospital admissions in Germany [4] and the second most
common reason for hospitalization in the USA among
those older than age 65 [7]. As a result, much attention has
focused on developing therapies that not only alleviate
symptoms, prevent adverse events, and improve quality of
life, but also prolong life.
Figure 3 shows the timeline for the introduction of
therapies used to treat heart failure. The earliest entries to
the list are digitalis and diuretics. Digitalis is rarely used in
current practice due to its narrow therapeutic window and
lack of data showing a survival benefit. In many patients,
risks outweigh benefits, particularly in those with hypo-
kalemia, hypothyroidism, or chronic renal disease. Beta-
blockers, angiotensin-converting enzyme inhibitors (ACE-
I) or angiotensin receptor blockers (ARBs), and aldos-
terone antagonists are currently considered optimal medi-
cal treatment (OMT) for heart failure due to the mortality
benefit afforded by these agents in most patients with
HFrEF. They also constitute the primary recommendations
in current guidelines on the treatment of heart failure with
reduced ejection fraction [8–10]. Another life-prolonging
medical regimen for heart failure is the use of hydralazine
together with a long-acting oral nitrate [11]. This combined
treatment is often used in lieu of ACE-I or ARB in patients
at risk of renal dysfunction. However, the combination of
hydralazine and isosorbide dinitrate is particularly effective
in African American subjects with heart failure and is a
first-line therapy in this group [12]. The use of diuretics,
particularly loop diuretics, is considered standard practice
in HFrEF to treat fluid accumulation peripherally or in the
lungs. Although not shown to prolong life, quality of life is
improved with diuretic therapy [13], resulting in continued
controversy about the risk/benefit with this treatment [14].
The most recent additions to the list of FDA-approved
medications for heart failure are ivabradine and a



















Fig. 1 Incidence of heart failure in the USA. An age-dependent
increase in new cases of heart failure is observed in older Americans.
The incidence is greater across ages in men compared to women.
(Adapted from Mozafarian et al. [1].)
























Fig. 2 Annual Incidence of heart failure by race in the USA. Heart
failure occurs most frequently in African Americans and Hispanics
with the lowest incidence in Chinese Americans. (adapted from
Mozafarian et al. [1].)
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combination of an ARB (valsartan) and a neprilysin inhi-
bitor (sacubitril) [15]. Ivabradine blocks sinus nodal pacing
inward cationic ‘‘f-currents,’’ thereby reducing heart rate
usually by 15 bpm as its primary mechanism of action [16].
Ivabradine displays a use-dependent effect (i.e., more
pronounced inhibition for faster sinus rates). Ivabradine
can reduce the composite outcomes of death and rehospi-
talization in patients with EF \35 % who are in sinus
rhythm with HR[70 when given together with guideline-
recommended doses of beta-blockers [17]. Ivabradine
represents the first new class of drugs approved by the FDA
for heart failure, in more than a decade. The combination
of valsartan/sacubitril has also been shown to reduce the
rate of CV death and heart failure hospitalization and has
been added to the list of FDA-approved therapies for CHF.
The numerous randomized controlled trials that have
defined the above-mentioned treatments that prolong life in
patients with heart failure have resulted in a variety of
regularly updated evidence-based guidelines of recom-
mended treatments [8–10, 18]. These treatments not only
reduce mortality and/or morbidity, but are also cost-ef-
fective [19, 20].
Device therapy for heart failure
In conjunction with medical treatment, device therapies
can also be life-sustaining. In a select population of
patients with severely debilitating heart failure for whom
life-expectancy is low without heart transplantation, left
ventricular assist devices can bridge patients to transplan-
tation. Evolution of device technology with miniaturization
and improved durability is creating a niche for LVAD as a
destination therapy but only in severe NYHA FC IV
patients.
For subjects with heart failure and ejection fractions less
than 35 % despite OMT, implantation of an internal car-
diac defibrillator (ICD) is indicated to prolong survival
based on several randomized controlled trials [21–23].
However, there is no effect on functional capacity or
symptoms with ICD placement. In the subset of symp-
tomatic heart failure patients with low EF and left bundle
branch block or otherwise wide QRS duration of 150 ms or
more, biventricular pacing (chronic resynchronization
therapy; CRT) can improve symptoms and survival [24].
The purported mechanism of action involves coordinating
the timing of contractility between ventricles and within
the LV. This benefit may be enhanced in patients with less
severe reductions in ejection fractions but does not extend
to those with normal or modestly prolonged QRS duration,
in whom CRT may worsen outcomes [25, 26]. In one
registry analysis, less than 10 % of patients admitted to a
hospital in heart failure met the electrocardiographic cri-
teria for CRT placement [27]. In a broader analysis of
clinical trials of heart failure with EF\35 %, QRS duration
of[120 ms is typically seen in only 14–47 % of patients,
averaging 30 % [18, 28]. However, in those trials, up to
30 % of patients meeting implantation criteria do not
derive a benefit from CRT [29, 30] initially, although long-
term follow-up may be required in some patients to observe
a benefit. Thus, a large gap exists in our therapeutic device
armamentarium for improving function and symptoms in
patients with moderate-to-severe systolic dysfunction and
normal or mildly prolonged QRS duration. This group
represents the majority of patients with symptomatic heart
failure patients on OMT and is precisely the population for
which CCM is designed to be of benefit (Fig. 4). Among
those patients with NYHA class 2 or 3 heart failure with EF
B35 %, nearly 80 % are estimated to be eligible for CCM
therapy (Fig. 4).
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Cardiac contractility modulation
Cardiac contractility modulation as delivered by Optimizer
IV is an established device that is of benefit to patients with
symptomatic heart failure on OMT and with normal or
mildly prolonged QRS duration, thus providing support for
the large complement of heart failure patients who do not
have an indication for CRT. CCM delivers a biphasic high-
voltage signal (7.5 V/22-ms duration) to the right ventric-
ular septum during the absolute refractory period (Fig. 5)
[31]. When administered for 5–12 h/day, this device
acutely augments dP/dt without raising oxygen consump-
tion, thereby improving cardiac efficiency [32, 33].
Chronic improvement in exercise performance and symp-
toms are reproducibly observed (see clinical studies section
below). These improvements are seen in patients with
normal or slightly prolonged QRS durations. Similar to
CRT, CCM may provide even greater improvement in
patients with less severe EF ([25 %) [34].
Implantation procedure
The implantation of a CCM unit is in many ways similar to
that of other cardiac implantable electrical devices (ICD’s
and pacemakers). The procedure is best performed under
moderate sedation in an OR grade sterile environment with
fluoroscopic guidance. For most patients, an ICD is already
present in the left prepectoral area, and therefore, most
implants would be performed via a contralateral right-sided
access. Current devices require the implantation of three
standard pacing leads. Two are placed in the RV and one in
the RA.
First, the skin and subcutaneous tissues in the (right)
deltopectoral groove are infiltrated with local anesthetics.
Next, using an extra-thoracic access technique, the axillary
and/or subclavian vein(s) are cannulated. The preferred
technique favors three separate access sites separated by at
least 1 cm to minimize lead-to-lead friction and future
binding. Three guide wires are advanced and placed into
the IVC. A skin incision is then performed along the three
wires, and the incision is carried down to the level of the
subcutaneous fascia. A device pocket is then fashioned in
the prepectoral area using blunt dissection. The pocket has
to be large enough to allow a fully relaxed fit of the device
caudal to the inferior margin of the incision. After
obtaining full hemostasis, the pocket is irrigated and then
























Fig. 4 Stratification of patients according to device-related thera-
peutic options. Of patients with HFrEF with NYHA class II or III,
36 % have an EF\35 %. Of those 30 % with wide QRS durations are
candidates for CRT. The remaining patients, including those who fail
CRT, constitute 79 % of those with EF\ 35 % and are eligible for
CCM. Adapted from multiple sources [18, 30, 64]
Fig. 5 CCM signal triggers from an atrial sensed impulse to augment
the next ventricular depolarization which is detected locally from the
onset of the QRS (A). After a delay of 30 ms (B) a biphasic impulse is
delivered (7.5 V amplitude, 22 ms duration; C), within the absolute
refractory period of the ventricle. (reproduced with permission from
Kleemann [31])
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packed with dry lap sponges. The leads will then be
sequentially placed using three peel-away sheaths intro-
duced over the guide wires. For each lead, mapping for an
ideal position is best performed before extending the fix-
ation screw at its tip. This is achieved by connecting the
lead pin to a PSA cable and moving each lead from spot to
spot until an adequate ventricular or atrial waveform is
recorded in the absence of far-field signals and in a position
that will provide likely anatomical stability and effective
delivery of CCM therapy.
Specifically, the RV lead tips should be placed along the
septal wall at least 2 cm apart. Proper placement is best
appreciated if multiple oblique views are used. The proposed
target zone is the septo-parietal trabeculations, in the inferior
portion of the septal RVOT.A roadmap can be created, and a
hand-injection RV angiogram performed via a balloon-tip-
ped open-lumen catheter. The catheter tip is initially placed
just under the pulmonic valve, and the injection is performed
while simultaneously dragging the balloon catheter from the
RVOT into the RV cavity along the septum.
The lead is then positioned using a Mond-type stylet
(with a primary J curve and a small posteriorly directed
secondary curve). The septal position of the lead is then
verified by oblique fluoroscopy views and pacing ECG
patterns.
In the 40 LAO view, the lead would be directed
rightward and posteriorly toward the spine. The septal
position is confirmed in a 30 RAO view.
On ECG, a deep S wave is noted in lead 1 (as opposed to
a tall R if pacing from the anterior wall) along with tall R
waves in V4–V6 [35] although this finding is debated.
The process is repeated for the second RV lead, the tip
of which is positioned slightly more apically or basally
(both tips should be in the mid-septal area with at least a
2-cm separation).
Electrical testing of the leads includes the standard
testing for pacemaker leads except that excellent sensing
function is valued more than pacing capture. Higher
impedances are preferred, but this is less important than
quality of sensing.
It is important to realize that proper lead tip positioning
is essential in a manner similar to LV lead tip positioning.
Based on the favorable genomic remodeling that occurs
with CCM, a septal tip position (as opposed to a remote site
in the RV free wall) would logically afford best signal
delivery to the left ventricle.
Once the RV leads are tested and secured into the
pocket, the atrial lead is placed with its tip in the RA
appendage or the lateral wall. With the PSA cable con-
nected to the lead pin, the lead tip position is varied to
identify optimal P wave sensing in an anatomically
stable position before extending the distal tip fixation
screw.
P wave sensing exclusive of far-field sensing is the
essential characteristic sought.
After fixing the atrial suture sleeve, the lead tips are
cleaned, dried, and connected to the CCM header. The
optimizer box is then placed in the prefashioned subcuta-
neous pocket with the recharging coil facing anteriorly.
Noninvasive testing is then performed to ensure proper
connectivity, sensing, and appropriately timed delivery.
Since most patients also have an implanted ICD, and
since the CCM generates a large voltage signal (7.5 V/22-
ms duration), testing for device–device interactions is
necessary. This testing requires that CCM be delivered
while the ICD is set with active tachycardia detection and
enhanced sensitivities. Intracardiac electrograms as read by
the ICD are then examined for evidence of sensing the
CCM signal. It is sensible to check for oversensing prior to
CCM device implant by delivering CCM signals with the
external simulator. If no oversensing is detected (and
therefore no lead repositioning is required), the optimizer
unit is then attached to the leads and placed in the pocket.
After this step, it is recommended to check again for
CCM–ICD interactions.
Implantation often includes testing for appropriate ICD
detection of VF waveforms which relies on automatic gain
control (AGC) of the sensing circuitry. With AGC, sensi-
tivity is maximized when signals are small (such as during
VF) and minimized when R waves are large such as during
NSR (to avoid double counting of R waves and/or T
waves). Thus, testing of CCM–ICD interactions in VF may
yield different results. It is again sensible, when the
patient’s hemodynamic status permits, to perform a VF
induction/rescue sequence while CCM therapy is active.
This is done to ensure that CCM therapy is immediately
and properly inhibited during VF lest stimulation signals be
sensed by the ICD. This could lead the ICD to misclassify
the VF event as sinus rhythm and thus withhold life-saving
shock delivery.
Once testing is complete, the CCM pocket is closed in
layers (we use 3 layers of absorbable sutures, including a
subcuticular layer and we then cover the wound with a
layer of medical adhesive ± a silver impregnated dress-
ing). An ice pack is then provided for pain, swelling and
bleeding control.
Mechanism of action of Optimizer therapy
The mechanism of action by which Optimizer improves
contractility, exercise tolerance, and symptoms appears
multifactorial with acute changes in calcium handling, and
chronic improvement in expression and phosphorylation of
key calcium regulatory pathways that increase contractility
and restore toward normal, the fetal gene expression profile
characteristic of heart failure.
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Acute increase in contractility
Within one beat following initiation of the CCM signal,
contractility in isolated rabbit papillary muscle strips
increases, but is attenuated as soon as the signal is with-
drawn [36]. This acute effect of CCM is also seen in car-
diac trabecular muscle of patients with severe heart failure
where CCM raises baseline contractility by over 50 % with
the onset of stimulation [36]. Within minutes of initiating
the CCM signal, myocardial ejection fraction and local
contractility typically increase. Using a dog model of heart
failure produced by coronary embolization, Morita et al.
[37] showed that by 1 h (earliest time point measured),
CCM increased EF from 31 ± 1 % at baseline to
41 ± 1 % with sustained further increases for up to 6 h. In
humans, a similar acute increase in contractility is observed
immediately after implantation, manifest as a rise in EF by
5 %. In fact, several clinical trials have utilized the acute
rise in EF to assess lead placement [38–40].
Insights into the mechanism of the acute rise in contrac-
tility with CCM can be gleaned from studies of calcium
handling within the cardiomyocyte. This is reviewed in
detail by Lyon et al. [41]. The benefit of CCM involves
upregulation of L-type calcium channels and improvement
of calcium uptake into the sarcoplasmic reticulum (SR),
thereby augmenting (1) extracellular calcium influx during
the subsequent membrane depolarization, and (2) calcium-
induced calcium release from the SR, respectively. Thus,
verapamil, which decreases voltage-dependent calcium
entry through the sarcoplasmic membrane, produces a
decrease in spontaneous and CCM-augmented contractile
effects [42]. Ryanodine which depletes the SR of calcium
also decreases CCM-induced calcium release through
ryanodine receptor-operated channels, thus inhibiting exci-
tation–contraction coupling and reducing contractility [42]
(Fig. 6). Together these data indicate that acute influences of
CCMon cardiac contractility occur viamultiplemechanisms
involving calcium handling in the cardiomyocyte.
Chronic effects of CCM in heart failure
In chronic heart failure models, CCM treatment increases
EF, SV, and LV dP/dt, and retards increases in LVEDV
and LVESV, while frankly decreasing LVEDP [43]
(Fig. 7). Thus, CCM improves the cardiomyocyte structure
and function in heart failure at the cellular and organ levels.
To understand how this improvement in cardiac function
occurs, it is important to recognize the change in cardiac
biochemistry that occurs with heart failure.
Chronic heart failure induces a change in the cardiomy-
ocyte phenotype to that of a more juvenile pattern via
reversion to a fetal gene program. Thus, in heart failure, there
is increased expression of BNP and the sodium–calcium
exchanger, with decreased expression of SERCA2A, alpha-
MHC, and phospholamban. Chronic use of CCM in animals
with heart failure causes biochemical reverse remodeling of
the fetal gene program back toward that of a normal adult
(Fig. 8) [44, 45]. In doing so, calcium handling within the
cardiomyocyte is improved. Upregulation of SERCA and
greater phosphorylation of phospholamban augment SR
uptake of calcium resulting in greater release of calcium
during the next depolarization, and therefore greater con-
tractility. Other components of calcium handling efficiency
in the cardiomyocyte are also improved by CCM including
upregulation of the ryanodine receptor and downregulation
of the sodium–calcium exchanger [41].
A potential consequence of chronic beneficial cardiac
remodeling with CCM is the retrospective clinical obser-
vation that QRS duration, which typically prolongs over
time in CHF, is maintained constant during CCM (over
2-year follow-up) [46]. This may be important since pro-
longation of the QRS in CHF is predictive itself of future
cardiac death [47]. Future prospective confirmation of this
potential benefit of CCM is warranted.
Local and remote cardiac effects of CCM
Changes in gene expression regulating calcium homeosta-
sis in cardiomyocytes are seen within 2 h of signal onset,
occur locally (in the region of the electrodes) when CCM is
active [45], and include an increase in expression of
SERCA2A and heightened phosphorylation of phospho-
lamban (PLN) [45]. However, after 3 months of CCM
treatment, both local and remote sites demonstrate the
same improvement in SERCA2A expression, PLN phos-
phorylation, and content of MYH6, RyR2, S100A1, sorcin.
This represents a general reversion away from the patho-
logical fetal gene expression of heart failure [41, 45].
Clinical results with device therapy for heart failure
Despite the substantial advances in treating HFrEF, mor-
bidity and mortality remain high with 50 % 5-year survival
rates, and 50 % 6-month readmission rates for heart failure
exacerbation [48]. For patients with symptomatic heart
failure despite optimal medical therapy, device therapy
offers promise. CRT is effective for those patients with
symptomatic heart failure and prolonged QRS and/or left
bundle branch block as described above. However, use of
CRT in patients with a narrow QRS duration can actually
increase mortality [25]. Approximately 20 % of patients
with heart failure have or develop a prolonged QRS
duration within the first year of diagnosis [49], and it is
estimated that only 30 % of established patients with EF
\35 % have a wide QRS (Fig. 4); therefore, only a
minority are eligible for CRT. This limits therapeutic
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options for patients still symptomatic on optimal medical
therapy and highlights the need for more treatment options.
Interestingly in the past 10 years, only two pharmacolog-
ical treatments have been approved for use for heart failure
in the USA and no new devices have received FDA
approval. CCM helps to address this gap in therapeutic
options (Fig. 4), has been evaluated in several clinical tri-
als, and is currently approved for use in Europe. This
section reviews the clinical data describing efficacy and
safety of CCM in patients with HFrEF.
Optimizer clinical trials
More than 10 clinical trials and ongoing registries spanning
4 generations of the OPTIMIZER device have provided
experience with nearly 3000 implanted patients from
whom we can document the effects of CCM in HFrEF.
These data support a specific clinical profile of patients
with HFrEF for whom CCM therapy may provide benefit
beyond OMT.
FIX-HF-3 was the first long-term study of CCM efficacy
[40]. Published in 2004, this unblinded observational study
enrolled 22 patients from multiple sites across Europe.
After 8 weeks of follow-up, there were improvements in
quality of life (Minnesota Living with Heart Failure
Questionnaire; MLWHFQ), LV ejection fraction, NYHA
classification, and 6-min walk test [40].
The results of FIX-HF-3 prompted the conduct of a
larger clinical trial, FIX-HF-4 [39]. This crossover study
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Fig. 6 Fundamental mechanism of action by which CCM improves
contractility in HFrEF. Key actions of CCM are shown in red and
include upregulation of SERCA2A, phosphorylation of phospholam-
ban, activation of L-type calcium channels, restitution of the
sodium/calcium exchanger, upregulation of metallomatrix proteins,
and reduction in basement membrane fibrosis. (Reproduced with
permission from Nature Reviews in Cardiology [41])
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Fig. 7 Chronic effect of CCM on cardiac structure and function in a
canine model of heart failure. Heart failure was induced by coronary
embolism, and dogs were maintained until EF stabilized below 35 %
for 2 weeks. CCM (or sham therapy) was started, and animals studied
at 3 months. CCM significantly reduced LVEDP and LVEDV, and
raised LV dP/dt, stroke volume, and LVEF compared to controls
where LV dP/dt and LVEF actually decreased. (Adapted from Morita
et al. [43].)
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cardiac resynchronization [50]. The study design was a
comparison between optimal medical therapy (OMT) and
OMT ? CCM in a crossover, double-blinded, prospective
manner with measurements made after 12 weeks of each
condition (CCM ON or CCM OFF). Inclusion criteria were
NYHA class II–III heart failure with EF\35 %. None of
the enrollees had an indication for CRT. Eighty were
assigned to group 1 (12 weeks of CCM ON followed by
12 weeks of CCM OFF), and 84 were assigned to group 2
(CCM OFF followed by CCM ON). Both groups were
matched in terms of baseline characteristics with average
ages of 58.9 ± 9.8 and 59.9 ± 10 in groups 1 and 2,
respectively. Over 80 % of both groups were men. Roughly
half in each group had an ICD. A small but similar number
of subjects dropped out from each group.
Primary endpoints were a change in peak oxygen con-
sumption (pVO2), and secondary endpoints were NYHA,
MLWHFQ, and 6-min walk distance [39]. Results are
summarized in Fig. 9. Peak oxygen consumption increased
similarly in both groups at 12 weeks by *0.4 mL/kg/min,
indicating a significant placebo effect, common among
double-blinded device trials. However, at 24 weeks, only
those subjects in group 2 (CCM OFF to ON) were able to
sustain the improvement in peak vO2, while those in group
1 (CCM ON to OFF) showed a decline (Fig. 9). Quality of
life measures responded similarly with MLWHFQ score
improving in both CCM and control groups at 12 weeks,
but the improvement was maintained only in those patients
with CCM ON for the final 12-week period [39]. This
suggests that a placebo effect is evident but that it is not
sustained for 24 weeks. The magnitude of the benefit from
CCM and CRT (MUSTIC trial) were similar, as was the
degree of CHF in both groups [50]. However, no placebo
effect was observed in the MUSTIC trial, possibly because
of single blinding. The safety profile was similar at the end
of the first 12 weeks in both groups. FIX-HF-4 demon-
strated in blinded fashion an improvement in exercise tol-
erance and QOL by CCM in patients with symptomatic























*p<0.05 vs Nl and CCM
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Fig. 8 CCM initiates biochemical remodeling and improves the fetal
gene program initiated in a canine model of heart failure. After
3 months of CHF, reduced expression (mRNA) of alpha-myosin
heavy chains, SERCA2A, and the ryanodine receptor, while upreg-
ulating brain natriuretic peptide. CCM normalized these changes.






Fig. 9 Changes in MLWHFQ
(upper left), peak VO2 (upper
right) and 6-min walk test
(bottom) in patients randomized
to CCM ON then CCM OFF
(blue) or CCM OFF then CCM
ON (red) from the FIX-HF-4
double-blinded randomized
controlled trial. At 12 weeks, a
significant improvement was
observed in both groups for
each parameter. At 24 weeks,
only those with CCM ON were
able to maintain the
improvement. These data
suggest a prominent placebo
effect at 12 weeks and a
sustained clinical beneficial
effect at 24 weeks of CCM.
(Reproduced with permission
from the European Heart
Journal [39])
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randomized controlled trial designed to obtain needed
efficacy and safety data for FDA approval.
FIX-HF-5 pivotal study is the largest clinical trial of
CCM performed to date and the first to extend efficacy and
safety observations up to 1 year. The study was conducted
within the USA across 50 centers using the Optimizer 3
CCM delivery system. It was a randomized longitudinal
comparison of OMT versus OMT ? CCM over the course
of 1 year with primary endpoint of ventilatory anaerobic
threshold (VAT), and secondary endpoints of pVO2,
MLWHFQ. Enrollment criteria included EF\35 %, QRS
duration\130 ms, NYHA III-IV, and use of stable doses
of OMT for at least 3 months. At the time the study was
designed, plans were also created to conduct a post hoc
analysis of the subset of subjects with EF [25 %. All
patients had an implanted ICD, and no enrollees had atrial
fibrillation [38]. Although randomized, the study could not
be blinded since only those in the CCM arm were
implanted. This decision was made due to ethical concerns
about conducting an invasive procedure to implant a device
which would intentionally remain ‘‘off’’ for at least a year.
The unblinded study design created a risk of an unbalanced
placebo effect in the CCM arm, and the FDA required use
of a primary efficacy endpoint that is less subjective,
namely ventilatory anaerobic threshold (VAT). This was
the first time that the FDA required VAT as a primary
endpoint in any clinical trial for heart failure. Part of the
reason that it is not commonly used is that in later stages of
heart failure, patients are not able to exercise sufficiently to
achieve anaerobic threshold (with lactate production).
Nonetheless, 428 patients were randomized, 213 to the
control group (OMT), and 215 to the CCM group. CCM
was delivered 5 h each day. Baseline characteristics were
similar between groups. Most suffered from ischemic car-
diomyopathy, and over 90 % were on standard medical
regimens for CHF including beta-blockers, ACE-I or
ARBs, and a loop diuretic. Efficacy data were analyzed by
intention-to-treat analysis.
The safety analysis showed a similar composite adverse
event rate for CCM (48.4 %) and OMT (52.1 %). Of these,
30 were serious adverse events related to the optimizer
system including lead fracture, dislodgment, infection, and
erosion. Over the course of 1 year, SAEs included
arrhythmias (in 25 and 29 subjects from OMT and CCM
groups, respectively), worsening heart failure (50 and 50
subjects, respectively), localized infection (29 and 27
patients, respectively), and general cardiopulmonary events
(46 and 42 patients, respectively). No difference in deaths
or individual adverse events was observed. However, when
focusing on the period between randomization and study
start date (during which time the implantation occurred), as
expected there were a few more adverse events in the CCM
group (22 events in 13 patients) compared to OMT (9
events in 8 patients).
The primary efficacy endpoint, VAT, was not different



























Fig. 10 Efficacy results from FIX-HF-5 study of CCM versus
optimal medical therapy (OMT) over 1 year. The primary endpoint
of ventilatory aerobic threshold was not met although significant
improvements in secondary endpoints of peak oxygen consumption,
MLWHF questionnaire, and NHYA classification were observed in
the CCM group versus OMT. (adapted with permission from Kadish
et al. American Heart Journal [38])
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0.14 ml/kg/min; Fig. 10) [38]. However, secondary end-
points of pVO2, MLWHFQ, and NHYA improved signif-
icantly at 1 year in the CCM group. In the planned
subanalysis of 150 patients with baseline EF [25 %, a
group exclusive of patients with very low EF who are
likely sicker and less able to exercise to AT, improvement
was observed in VAT, pVO2, NYHA, EF, and 6-min walk
test with CCM versus OMT. In each case, the improvement
was greater than that seen in the entire cohort (Fig. 11).
This provocative hypothesis-generating result suggests that
CCM may provide an added benefit in symptomatic
patients already on OMT who have moderate reductions in
ejection fraction.
Based on the clinical trials already conducted, two
meta-analyses have been performed. The earlier analysis
by Kwong et al. [51]. pooled 3 studies looking at out-
comes of all-cause mortality, all-cause hospitalizations,
and adverse effects compared to OMT or OMT? sham
treatment. The authors concluded that CCM, while pro-
viding no primary outcome benefit, was not associated
with worsening prognosis [51]. The primary efficacy
outcomes measures were available in a limited number of
subjects, and no effect of CCM was observed. Adverse
effects were not different between groups. Interestingly,
MLWHFQ, NYHA, pVO2, and 6-min walk test were not
analyzed due to lack of data for these outcomes. This
meta-analysis was performed on grouped data, and indi-
vidual patient data were not used.
A second and more recent meta-analysis was performed
by Giallauria et al. [52] using a similar search strategy to
Kwong, resulting in the inclusion of 641 subjects from 3
trials. Even though many of the same data were included in
each analysis, Giallauria but not Kwong had access to
individual data values, improving the quality of the anal-
ysis. In this study, a significant benefit of CCM on out-
comes of pVO2, 6-min walk test, and MLWHFQ was
observed (Fig. 12).
Collectively, these clinical trials demonstrate a favor-
able efficacy and safety profile for CCM which parallels
that observed in patients with CRT (Fig. 13). However,
efficacy with CRT is restricted to subjects with LBBB or
very prolonged QRS. Thus, CCM fills a critical gap in our
arsenal of therapies to improve symptoms and exercise
capacity in patients with heart failure.
Fig. 11 Subgroup analysis of
FIX-HF-5 focusing on 150
subjects with LVEF[ 25 %.
Improvements in VAT, pVO2,
NYHA, LVEF, and 6-min walk
test were observed. For
comparison, orange bars
represent amount of
improvement seen in the
primary study. (adapted with
permission from Kadish et al.
American Heart Journal [38])
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Long-term outcomes
To date, there have been no prospective trials of CCM with
mortality as a primary outcome. However, with nearly
3000 implants over a period of more than a decade, there
have been several opportunities to observe long-term
mortality in patients chronically treated with CCM. Four
such published observations are described in this section.
The first of these studies was conducted by Schau et al.
[53]. between 2003 and 2010 as a retrospective evaluation of
54 consecutively implanted patients. Patients had moderate-
to-severe heart failure with NYHA class III or IV symptoms
and average LVEF of 23 ± 6 %. Patients were followed
every 3 months for approximately 3 years. Twenty-four
patients died during follow-up (18.4 %/year). All-cause
mortality was equivalent to that predicted by the Seattle
Heart Failure Model [53], a well-validated scoring system
that utilizes a diverse group of clinical parameters most of
which were available from the CCM patient records.
The second and more recent study by Kuschyk et al.
[54] was also conducted at a single site (Mannheim, Ger-
many) with a larger number of patients (81 consecutive
patients implanted with a CCM device between 2004 and
2012) who were also followed for 3 years. Patient acuity
was similar to that described above with baseline
EF = 23 ± 7 % and most presenting with NHYA III or IV
symptoms. Kuschyk [54] found long-term improvement in
NYHA, MLWHFQ, LVEF, LVEDD, LVESD, and NT-
proBNP between baseline and follow-up. Kaplan–Meier
survival curves demonstrated a significant improvement in
mortality with CCM compared to predicted mortality rates
with OMT from the MAGGIC score (14).
A limitation of the MAGGIC scoring system is that it is
based on data from a time when ICD use was not routine,
Fig. 12 Meta-analysis of major endpoints from key clinical trials of
CCM versus optimal medical therapy. Data were analyzed using
individual data points. A significant overall benefit was observed
favoring CCM for pVO2 and MLWHF questionnaire, with a nearly
significant benefit for 6-min walk test. (reproduced with permission
from Giallauria et al. [52])
Heart Fail Rev (2016) 21:645–660 655
123
and therefore may overestimate mortality when compared
to modern-day studies. For this reason, the Kaplan–Meier
curve was adjusted to consider every incidence of VT and
VF as if it were a mortality event. Even with this strict
overcorrection, the event rate in the study population was
13.1 % compared to 18.4 % predicted by MAGGIC at
1 year, and 32.1 versus 40 % at 3 years, respectively.
As described in the secondary analysis of FIX-HF-5,
CCM appears to confer a greater benefit in patients with EF
[25 %. A third and very recently published long-term
outcome study addressed this specific subpopulation. Liu
et al. [55] examined outcomes in 41 consecutive heart
failure patients with EF\40 % in whom a CCM device
was implanted. Follow-up extended 6 years and cases were
matched 1:1 with controls with respect to age, gender, EF
at baseline, medications, follow-up duration and cause of
heart failure. The primary endpoint was all-cause mortality.
Secondary endpoints included heart failure hospitaliza-
tions, cardiovascular deaths, and composite endpoints.
CCM and control groups were well balanced with average
EF = 28 %. All-cause mortality was lower in the CCM
group (Fig. 14). Interestingly, when patients were stratified
by EF, no difference was observed in those with EF less
than 25 %, but a robust reduction in mortality was
observed in the CCM group with EF between 25 and 40 %
(Fig. 14). Similar improvements in the entire group and
those with higher ejection fractions were seen for cardio-
vascular deaths and for the composite outcome of heart
failure and death. For heart failure hospitalizations, there
was no difference between CCM and control groups across
the entire cohort or for those with lower ejection fractions.
However, a significant reduction was observed with CCM
in patients with EF between 25 and 40 %.
The fourth analysis of long-term survival with CCM was
recently published by Kloppe et al. [56]. The investigative
team evaluated outcomes in 68 consecutive heart failure
patients (NYHA II or III) implanted at one of two sites in
Germany with CCM devices between 2002 and 2013.
Outcomes at 4.5 years were compared with the Seattle
Heart Failure Model for matched subjects. Mean LVEF
was 26 % ± 6 %; 78 % of patients had an ICD implanted
during the study follow-up. The average patient age was
61. Mortality rates at 1, 2, and 5 years were lower with
CCM than predicted by SHFM (Fig. 14).
Collectively, these findings suggest a long-term benefit
of CCM for cardiovascular and all-cause mortality and are
congruent with prior subanalyses suggesting that CCM is
particularly beneficial in patients with moderate heart
Fig. 13 Comparison of the effects of CCM and CRT on peak VO2.
Studies to the left of the red line utilized CCM (narrow QRS), while
those to the right employed CRT (wide QRS). A similar magnitude of
effect was observed in studies from each device. (adapted with
permission from European Heart Journal [65])
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Fig. 14 Mortality rates for CCM versus OMT or comparator groups
after long-term follow up. Based on the nature of each study, data are
presented at 1, 2, 3, and 5 years following device implantation.
Results from 5 groups of subjects from 4 clinical trials are displayed.
At the longest follow-up time point for each study, mortality rates
were the same or lower in the CCM group compared to the medically
treated comparator. In one study mortality with CCM was higher in
year 2. The benefit was consistent across a broad spectrum of severity
of disease (Schau et al. [53] enrolled 54 patients with more severe
heart failure—NYHA III–IV, EF = 23 %); Kloppe et al. [56]
followed 68 patients with NYHA II–III, mean EF = 26 %); Kuyschyk
et al. [54] studied 81 patients NYHA II–IV, EF = 23 %, 14 % of
patients had prolonged QRS duration), while Liu et al. [55] tracked 41
subjects with NYHA III and EF = 27 %; ICD use was low in both
groups. Comparator groups for each study are as follows: Schau—
Seattle Heart Failure Model; Yu, and Yu (EF[ 25 %)—subjects on
medical therapy alone from the same database matched for age,
gender, etiology of heart failure, and duration of heart failure;
Kucyck—MAGGIC risk score; Kloppe—Seattle Heart Failure Model
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failure. They also support the need for a prospective ran-
domized trial to define a mortality benefit. An ongoing
randomized controlled trial will address the effect of CCM
in patients with EF between 25 and 40 % on exercise tol-
erance, quality of life, and symptoms [57].
Special applications and evaluations
CCM has also been tested using different stimulus
parameters, and in special populations.
Duration of stimulus The choices for daily duration of
treatment have been expanded. This is based on a recently
published randomized trial of 5 versus 12 h per day of
impulse delivery [58]. In this double-blinded pilot study,
Kloppe and colleagues studied 19 subjects who were ran-
domized to receive CCM active impulses either for 5 or
12 h/day. Both groups showed similar improvements in
MLWHFQ and NYHA, with trends toward improved
pVO2 [58]. There were no differences between groups. The
maintained benefit from shorter durations of CCM stimulus
delivery helps to reduce the battery recharge frequency and
may allow some patients with frequent ectopy to still be
eligible for implantation.
CRT failures CCM has been tested in the 20 % of
patients who fail CRT (nonresponders). In one study,
sixteen such patients were treated with CCM and fol-
lowed for an average of 147 ± 80 days [59]. The patients
were older (65 ± 9 years of age) and had more severe
heart failure (EF = 27.3 ± 7.4 %) than those recruited
for the clinical trials described above. At follow-up, there
were significant improvements in NYHA class (3.4–2.8)
and ejection fraction (27.3–31.1 %). No electrical inter-
ference was noted between CCM and CRT. However, the
adverse event rate was high with 3 patients suffering
sudden death, 4 developing atrial fibrillation, and two
pneumonia. This event rate likely reflects the heightened
acuity of these patients who had failed both OMT and
CRT therapies.
Heart failure with preserved ejection fraction (HFpEF)
accounts for up to 50 % of all symptomatic heart failure
patients. However, conventional heart failure therapy is
ineffective or frankly harmful in this condition, and cur-
rently, there is no demonstrated beneficial treatment. With
this in mind, a very early and provocative report by
Tschope describes the experience with CCM in two
patients with symptomatic HFpEF [60]. Endomyocardial
biopsies and exercise testing were performed in both cases
before and after CCM. Improvements were observed in
NHYA classification, 6-min walk testing, EF, and
MLWHFQ. There was also an increase in diastolic relax-
ation and EF reserve by dobutamine challenge.
In diastolic heart failure, underphosphorylation of the
cardiac protein titin results in fibrosis and stiffening. CCM
therapy upregulated phosphorylated titin, with similar
improvement in troponin 3 and myosin light chain 2 [60].
CCM resulted in a reduction in cardiac fibrosis as evi-
denced by decreased collagen expression by over 20 %.
This exploratory study indicates a multi-pronged beneficial
effect of CCM in patients with diastolic heart failure.
Atrial fibrillation Atrial fibrillation is a frequent and
particularly difficult complication in heart failure, resulting
in excessive symptoms due to loss of synchrony in filling
an often stiff left ventricle during a typically shortened
diastolic period. Although permanent atrial fibrillation
prevents the optimizer stimulus due to loss of the atrial
sensing, current versions of the device can overcome this
limitation, allowing effective impulse delivery in the
presence of atrial fibrillation. Early experience with this
novel algorithm (linked to the presence of a CRT device
impulse) was published by Roger et al. [61]. who described
use of CCM in 5 patients who developed permanent atrial
fibrillation at or after optimizer implantation. Gating off of
the CRT signal, successful CCM therapy was implemented
for 12 h/day. After more than a year follow-up, all patients
were alive and in each case the clinical condition
improved. All 5 showed improvement in NHYA class and
MLWHF questionnaire. EF increased or remained
unchanged in all subjects. Adverse effects were minimal
with one patient developing moderate TR. It was concluded
that CCM is a promising treatment for CHF with atrial
fibrillation, to improve cardiac function and symptoms.
Future adjustments in sensing algorithms should allow for
the delivery of CCM without the use of the subterfuge of
asynchronous pacing into a fibrillating atrium.
Cost-benefit analysis Evidence-based guidelines increas-
ingly incorporate cost-benefit analysis into crafting rec-
ommendations. Heart failure is a prime target for cost
analysis since the presence of heart failure may double or
triple the cost of a patient’s hospitalization [62]. A recent
economic evaluation of CCM was conducted for the UK
based on a Markov model using data from prospective
CCM trials comparing CCM ? OMT with OMT alone
[63]. Estimates of life years (LY), quality-adjusted life
years (QALY), and treatment costs were made. Clinical
variables incorporated into the model included peri-implant
complication rates, NYHA class over time, and MLWHFQ
from which mortality and hospitalization rates were esti-
mated. Total calculated cost for CCM ? OMT was
£37,467 versus £16,885 for OMT alone. Life years gained
were calculated as 7.96 for CCM ? OMT versus 7.0 for
OMT alone so that QALY was 5.26 versus 4.0, respec-
tively. This resulted in an incremental cost per QALY of
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123
£16,405. These calculations are in line with QALY benefit
with CRT and ICD devices and are below the threshold
cost used by the UK of between £20,000 and £30,000 per
QALY and those used typically in the USA of *$50,000
[19] for a beneficial therapy. Based on these results, the
authors concluded that CCM therapy may be considered
cost-effective. However, a more refined analysis should be
made with direct mortality and hospitalization data from
large prospective RCTs.
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